Levitra

Vardenafil, the active ingredient in Levitra, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a tablet for buccal use. It treats erectile dysfunction in adult males by enhancing penile blood flow during sexual stimulation. GNH USA supplies Levitra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levitra is a phosphodiesterase type 5 inhibitor used to manage erectile dysfunction, a condition affecting male sexual performance.

Erectile dysfunction (organic): Improves the ability to achieve and maintain an erection sufficient for sexual activity. Erectile dysfunction (psychogenic): Restores erectile function when the cause is primarily psychological. Erectile dysfunction (diabetes‑associated): Enhances erectile response in men whose condition is related to diabetes.

Common Side Effects: - Headache: mild to moderate pain often described as tension‑type. - Flushing: warmth and redness, typically of the face and neck. - Nasal congestion: sensation of a blocked nose. - Dyspepsia: mild stomach discomfort or indigestion.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention. - Sudden vision loss: may indicate non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: abrupt decrease or loss of hearing, sometimes accompanied by tinnitus.

Before starting Levitra, patients should consider several safety factors. - Cardiovascular assessment: evaluate heart disease risk and recent cardiac events. - Nitrate therapy: avoid concurrent use with nitrates due to risk of severe hypotension. - Blood pressure monitoring: use cautiously in uncontrolled hypertension or hypotension. - Alcohol consumption: limit excessive intake as it may increase side‑effect frequency. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levitra can interact with several medicines that affect blood pressure or metabolism.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause dangerous drops in blood pressure. - Guanylate cyclase stimulators (e.g., riociguat): potent additive hypotensive effect. - Protease inhibitors (e.g., ritonavir): increase vardenafil plasma levels.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin): may cause additive blood‑pressure lowering. - Other PDE5 inhibitors (e.g., sildenafil): concurrent use can raise risk of adverse reactions.